UK MHRA · June 18, 2026

Warning on promoting newly licensed prescription-only medicines and unlicensed medicines for weight management

MHRA, ASA and GPhC warn businesses against unlawful promotion of newly authorised and unlicensed weight-management medicines.

High obligation Sector Pharmaceuticals Market Access & Reimbursement UK Pharmaceuticals

The MHRA, Advertising Standards Authority, and the General Pharmaceutical Council have issued a warning to businesses seeking to promote newly authorised medicines, as well as those that do not yet have a marketing authorisation.

Read the official source ↗

Published by UK MHRA. HealthSignal links to the original document; the summary above is extracted from the source text.